What a HER2 2+ Test Result Means for Your Treatment

A HER2 2+ result on immunohistochemistry (IHC) means your tumor showed a borderline level of HER2 protein, and your oncology team cannot yet tell whether the cancer qualifies as HER2-positive or falls into a newer treatment-relevant category called HER2-low. The result is officially “equivocal,” and it triggers a second round of testing, usually a technique called FISH or another form of in situ hybridization, to check whether the HER2 gene itself is amplified. What that second test reveals determines which therapies are on the table, and the options have expanded considerably in recent years.

Why a 2+ Score Sits in the Middle

When a pathologist examines a tumor biopsy for HER2, they typically start with immunohistochemistry, a staining method that reveals how much HER2 protein sits on the surface of cancer cells. The result is scored on a simple scale: 0 means no detectable staining, 1+ means faint or barely visible staining, 2+ means moderate staining that is complete around the cell membrane but not intensely dark, and 3+ means strong, uniform staining. A score of 3+ is considered HER2-positive on its own. A score of 0 or 1+ is considered HER2-negative (though, as we will see, this distinction now matters for newer drugs). A score of 2+ lands in a gray zone where the protein level alone is not enough to call the tumor positive or negative.

HER2 is a transmembrane receptor involved in cell growth and survival. When a tumor overexpresses it or carries extra copies of the gene, that overactivity drives aggressive behavior and is associated with a worse prognosis if untreated.¹ The entire point of HER2 testing is to figure out whether that overactivity is present, because targeted drugs can specifically block it. A 2+ score is the result that demands the most follow-up before treatment decisions can be made.

The Second Test That Follows a 2+ Result

Current guidelines from ASCO and the College of American Pathologists require that every IHC 2+ breast cancer undergo a follow-up test with in situ hybridization, most commonly fluorescence in situ hybridization (FISH).² FISH looks directly at the DNA inside tumor cells to count how many copies of the HER2 gene are present. If the gene is amplified, meaning there are significantly more copies than normal, the tumor is reclassified as HER2-positive. If it is not amplified, the tumor falls into the HER2-low category.

This two-step process is called reflex testing, and it matters more than many patients realize. One study evaluating patterns of HER2 testing found that reflex testing of IHC 2+ cases identified roughly 10% additional HER2-positive tumors that would have been missed without the second step.³ That fraction may sound small, but for those patients, the correct classification opens the door to highly effective targeted therapies. FISH testing is time-consuming and resource-intensive, which has raised questions about whether it could ever be skipped in certain situations, but the clinical stakes are high enough that guidelines firmly require it for every 2+ case.⁴

If FISH Shows Amplification

When an IHC 2+ tumor turns out to be FISH-positive, the cancer is treated as HER2-positive. That means you become a candidate for HER2-targeted therapies such as trastuzumab, pertuzumab, and the antibody-drug conjugate T-DM1, depending on your cancer stage and treatment history. A large meta-analysis of over 13,000 women in randomized trials confirmed that trastuzumab in early-stage HER2-positive breast cancer significantly reduces the risk of recurrence, though the benefit was concentrated in tumors with HER2-to-CEP17 ratios above 2.0.⁵

There is a nuance here worth knowing. Among patients classified as HER2-positive, those who scored 2+ on IHC and then tested FISH-positive appear to have slightly worse overall survival compared with those who scored 3+ on IHC. A national database analysis found that women with IHC 2+ and FISH-positive tumors had about a 22% higher risk of death than those with IHC 3+ tumors.⁶ This does not mean the targeted treatment is less effective for these patients, but it suggests that IHC 2+/FISH-positive tumors may behave somewhat differently from IHC 3+ tumors, possibly due to lower overall HER2 protein levels or more variability within the tumor.

If FISH Shows No Amplification

This is where things have changed most dramatically. Until a few years ago, an IHC 2+ tumor that tested FISH-negative was simply labeled HER2-negative and treated like any other HER2-negative cancer. The classification system was binary: positive or negative, and that was that.⁷ But newer antibody-drug conjugates, especially trastuzumab deruxtecan (T-DXd, brand name Enhertu), have shown that even cancers with low levels of HER2 expression can respond to targeted treatment. An IHC 2+ tumor without gene amplification now falls into the HER2-low category, along with IHC 1+ tumors.⁸

Almost half of all breast cancers previously called HER2-negative actually show some degree of HER2 protein expression on IHC and would now qualify as HER2-low.⁹ This redrawing of the map has been driven entirely by the development of drugs that work in this population.

How Trastuzumab Deruxtecan Changed the Landscape

The pivotal trial behind this shift was DESTINY-Breast04, which tested trastuzumab deruxtecan against standard chemotherapy in patients with HER2-low metastatic breast cancer who had already been through prior treatment. In the overall study population, patients receiving T-DXd lived a median of about 23 months compared with roughly 17 months for those on standard chemotherapy. Progression-free survival nearly doubled, from about 4 months to about 9 months.¹⁰ Long-term follow-up data confirmed these results held up, with the survival benefit remaining consistent after more than two and a half years of observation.¹¹

The benefit was seen in both hormone receptor-positive and hormone receptor-negative patients, though the hormone receptor-negative group was smaller and the results there did not reach statistical significance on their own. The hormone receptor-negative cohort still showed a meaningful trend: median overall survival was about 17 months with T-DXd versus roughly 8 months with standard chemotherapy.¹¹

What makes T-DXd effective in tumors with so little HER2 is partly its design. Older HER2-targeted drugs like trastuzumab block the HER2 receptor from the outside, so they need the receptor to be present in large numbers to do much. Antibody-drug conjugates work differently: they use the antibody as a delivery vehicle to bring a powerful chemotherapy payload directly into the cancer cell. T-DXd carries a topoisomerase inhibitor that, once released, can also seep into neighboring cells and kill them, an effect called the bystander effect.¹² This bystander activity means even tumors where only some cells express HER2 can respond to the drug, which is a key reason T-DXd works in HER2-low cancers while earlier HER2-targeting drugs did not.¹³

The HER2-Ultralow Frontier

Even beyond HER2-low, the picture continues to evolve. The FDA recently approved T-DXd for hormone receptor-positive metastatic breast cancer based on DESTINY-Breast06, a trial of 866 patients that included both HER2-low and a newer category called HER2-ultralow. HER2-ultralow tumors show the faintest trace of staining on IHC, falling into a zone between a true zero and a clear 1+. This approval marked the first time an FDA indication has specified the HER2-ultralow category, and a companion assay to identify these patients was approved alongside the drug.¹⁴

This expansion means the distinction between IHC 0 (truly no staining) and even the faintest hint of HER2 expression is becoming clinically relevant in ways it never was before. The updated ASCO/CAP guidelines acknowledge this shift, noting that while it may be premature to create formal new result categories, best practices to distinguish IHC 0 from 1+ are now important for treatment decisions.² If you received a 2+ result, you are well within the range where these newer drugs have proven benefit, regardless of whether your FISH result comes back positive or negative.

Why a 2+ Score Is Especially Hard to Get Right

One of the less-discussed realities of HER2 testing is that the 2+ range is where pathologists disagree with each other the most. The score depends on a human expert looking through a microscope and judging staining intensity, which is inherently subjective. IHC 2+ tumors are also the most likely to show intratumoral heterogeneity, meaning different parts of the same tumor express HER2 at different levels. In breast cancer, tumors with equivocal (2+) IHC staining are strongly associated with low-level or mixed HER2 gene amplification and heterogeneous staining patterns.¹⁵ A more recent study found that this heterogeneity, defined as having at least three distinct staining intensities within a tumor, was present in the vast majority of low-level amplification cases but in only about a quarter of strongly positive tumors.¹⁶

Pre-analytical factors add another layer of uncertainty. How a tissue sample is handled before it reaches the pathologist’s slide can affect the score. Delays in fixing (preserving) the tissue or fixing it for too long can degrade HER2 staining. Experiments using gastric cancer models showed that leaving specimens unfixed at room temperature for 24 hours reduced HER2 IHC scores, with some 2+ tumors dropping to 1+ and some 1+ tumors dropping to 0.¹⁷ Overly long fixation times caused similar downgrades. These kinds of artifacts mean that a 2+ result is not always a clean reflection of the tumor’s biology; it can also be an artifact of how the biopsy was processed.

The economic consequences of inaccurate results are substantial. One analysis estimated that among women diagnosed with early-stage breast cancer in a single year, roughly 3% received false-positive HER2 results and about 2% received false-negative results, costing roughly $417 million and $575 million in unnecessary or missed treatment expenses, respectively.¹⁸ False negatives are especially costly because they deprive patients of targeted therapy that could have improved outcomes.

HER2 Status Can Change Over Time

If your 2+ result came from a metastatic site or a recurrence rather than the original primary tumor, the result may genuinely differ from what was seen at initial diagnosis. A study comparing paired primary and recurrent breast tumors found that HER2 status changed in over a third of cases, with the HER2-low category becoming more common in recurrences than in original tumors.¹⁹ Separate research found that about 10% of patients had discordant HER2 status between their primary breast cancer and a later metastasis, with the majority of the switches going from negative to positive.²⁰

This is why guidelines now recommend retesting HER2 when cancer recurs or metastasizes. The finding is not just academic: patients who acquired HER2 positivity at the metastatic site and received anti-HER2 therapy had different outcomes from those whose status remained unchanged.²¹ If your current 2+ result looks different from an earlier test, that discordance itself is a piece of clinically useful information rather than a testing error.

HER2 2+ in Gastric and Other Cancers

HER2 testing is not exclusive to breast cancer. In gastric and gastroesophageal cancers, HER2-positive tumors are similarly treated with trastuzumab in combination with chemotherapy.²² But HER2 in gastric cancer has its own quirks. The scoring criteria are different from breast cancer: gastric cancer cells can show incomplete membrane staining and still count as positive, whereas breast cancer scoring requires complete membrane staining. Applying breast cancer scoring rules to gastric tumors can lead to undercounting HER2-positive cases by a wide margin.²³

Intratumoral heterogeneity tends to be even more pronounced in gastric cancer. One study found that among gastric tumors scoring IHC 2+ or 3+, over 70% showed heterogeneous HER2 overexpression within the same tumor, and the pattern was most common in 2+ cases.²⁴ If you have gastric cancer with a 2+ IHC result, the same reflex-to-FISH pathway applies, but the context and the challenges are somewhat different from breast cancer.

AI Tools Are Improving Scoring Consistency

Because a 2+ score sits at the boundary where human judgment is most variable, there is growing interest in using artificial intelligence to assist pathologists. A large multi-reader study found that when pathologists used an AI tool for HER2 scoring, agreement among readers increased from 75% to nearly 84%, and overall accuracy improved modestly as well.²⁵ A systematic review and meta-analysis of AI performance across multiple studies found that for the 2+ score specifically, AI achieved high accuracy, with pooled sensitivity of 0.89 and specificity of 0.96.²⁶

These tools are not replacing pathologists. Rather, they are serving as a second set of eyes in cases where the scoring is most ambiguous. Given how much rides on whether a tumor is scored 2+ versus 1+ or 3+, especially now that each of those scores feeds into different treatment pathways, any improvement in consistency and accuracy at the 2+ boundary has real clinical value.

Liquid Biopsy as a Complementary Approach

For patients with advanced or metastatic breast cancer, repeated tissue biopsies to recheck HER2 status are not always feasible. Liquid biopsy, which analyzes tumor-derived DNA circulating in the bloodstream, offers a less invasive alternative. One study comparing digital PCR on blood samples with standard tissue-based IHC/FISH found that the liquid biopsy approach detected HER2 amplification with about 44% sensitivity and 84% specificity.²⁷ That sensitivity is too low to replace tissue testing, but the authors suggested that a liquid biopsy after a negative tissue result might catch false negatives, particularly in patients with late-stage disease or those who have relapsed. As a complement to tissue biopsy rather than a replacement, circulating tumor DNA analysis is becoming another tool in the monitoring toolkit, especially when biopsy access is limited or the clinical picture does not match the pathology report.